Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.56 |
| ▸ | THRB | P10828 | 8/20 | 0.56 |
| ▸ | RARB | P10826 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RARA | P10276 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9257866 | 0.97 | L3MBTL1 (0.54) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9251080 | 0.97 | HSD17B10 (0.54) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9252434 | 0.95 | THRA (0.55) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9259982 | 0.94 | L3MBTL1 (0.50) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9259775 | 0.92 | HSD17B10 (0.53) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9255950 | 0.92 | GAA (0.51) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL9256025 | 0.92 | HSD17B10 (0.56) | THRATHRBRARBHSD17B10KMT2A | |
| SCHEMBL963847 | 0.90 | THRA (0.67) | THRATHRBRARBHSD17B10MEN1 | |
| SCHEMBL10866320 | 0.89 | L3MBTL1 (0.51) | THRATHRBRARBHSD17B10KMT2A | |
| SCHEMBL965858 | 0.88 | THRA (0.70) | THRATHRBRARBHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-5385693-A | Having rapid response and low phase transition temperature | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0357372-B1 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL CO (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5264151-A | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0357372-A2 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | THRA 3096/4885THRB 2021/4885RARB 1319/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | THRA 3629/4885THRB 3218/4885RARB 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.